Merck’s Fosamax on Trial Again After First Case Halted

The second trial over claims Merck & Co. hid risks that its Fosamax osteoporosis drug could cause femur fractures is scheduled to start next week after the plaintiff in the first case suffered a health problem.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.